SCHEMBL4074223

SCHEMBL4074223

Fc1cc2ncsc2cc1Br

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.38
RAB9A P51151 6/20 0.38
ALDH1A1 P00352 1/20 0.38
HSD17B10 Q99714 1/20 0.38
KDM4E B2RXH2 1/20 0.37
HKDC1 Q2TB90 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ILK Q13418 1/20 0.35
DYRK1A Q13627 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
APP P05067 1/20 0.35
MAPK14 Q16539 1/20 0.35
EGFR P00533 1/20 0.35
TGFBR1 P36897 2/20 0.34
VRK1 Q99986 1/20 0.34
PTK6 Q13882 2/20 0.32
STIM1 Q13586 1/20 0.32
ORAI1 Q96D31 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29703396 0.92 NPC1 (0.38) NPC1RAB9AALDH1A1HSD17B10KDM4E
SCHEMBL22366924 0.92 NPC1 (0.38) NPC1RAB9AALDH1A1HSD17B10KDM4E
SCHEMBL27921861 0.83 ALDH1A1 (0.43) NPC1RAB9AALDH1A1HSD17B10KDM4E
SCHEMBL12121770 0.76 TGFBR1 (0.44) NPC1RAB9AALDH1A1HSD17B10KDM4E
SCHEMBL15689087 0.76 DYRK1A (0.42) NPC1RAB9AALDH1A1HSD17B10KDM4E
SCHEMBL22655616 0.76 MEN1 (0.48) NPC1RAB9AALDH1A1HSD17B10KDM4E
SCHEMBL4075601 0.76 ALDH1A1 (0.38) NPC1RAB9AALDH1A1HSD17B10KDM4E
SCHEMBL3735091 0.76 NPC1 (0.38) NPC1RAB9AALDH1A1HSD17B10KDM4E
SCHEMBL4296143 0.75 ALDH1A1 (0.52) NPC1RAB9AALDH1A1HSD17B10KDM4E
SCHEMBL4560336 0.73 ALDH1A1 (0.50) NPC1RAB9AALDH1A1HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4658656-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES Beone Medicines I GmbH (CH) 2025-12-10 EP disclosed
US-20250346597-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES BEONE MEDICINES I GMBH (CH) 2025-11-13 US disclosed
EP-4457224-A1 HETEROCYCLIC COMPOUNDS BeiGene Switzerland GmbH (CH) 2024-11-06 EP disclosed
US-20240327417-A1 HETEROCYCLIC COMPOUNDS BEIGENE SWITZERLAND GMBH (CH) 2024-10-03 US disclosed
WO-2024160276-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES BEIGENE, LTD. (KY) 2024-08-08 WO disclosed
CN-118451073-A Heterocyclic compounds 百济神州有限公司 2024-08-06 CN disclosed
WO-2023125681-A1 HETEROCYCLIC COMPOUNDS BEIGENE, LTD. (KY) 2023-07-06 WO disclosed
WO-2023125681-A1 HETEROCYCLIC COMPOUNDS BEIGENE, LTD. (KY) 2023-07-06 WO disclosed
US-20210315869-A1 COMPOUNDS AND METHODS FOR CSK MODULATION AND INDICATIONS THEREFOR PLEXXIKON INC. 2021-10-14 US disclosed
WO-2021202900-A1 1,6-NAPHTHYRIDINE COMPOUNDS AND METHODS FOR CSK MODULATION AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2021-10-07 WO disclosed
US-8507489-B2 Bicyclic triazoles as protein kinase modulators SGX PHARMACEUTICALS, INC. (US) 2013-08-13 US disclosed
US-8507489-B2 Bicyclic triazoles as protein kinase modulators SGX PHARMACEUTICALS, INC. (US) 2013-08-13 US disclosed
US-8507489-B2 Bicyclic triazoles as protein kinase modulators SGX PHARMACEUTICALS, INC. (US) 2013-08-13 US disclosed
EP-2084162-B1 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS INC (US) 2012-09-12 EP disclosed
US-20090258855-A1 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. 2009-10-15 US disclosed
US-20090258855-A1 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. 2009-10-15 US disclosed
US-20090258855-A1 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. 2009-10-15 US disclosed
CN-101553490-A Bicyclic triazoles as protein kinase modulators SGX PHARMACEUTICALS INC (US) 2009-10-07 CN disclosed
EP-2084162-A2 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2009-08-05 EP disclosed
WO-2008051808-A2 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240327417-A1 HETEROCYCLIC COMPOUNDS NFATC1, CD4, ACIN1 NPC1 1729/4885RAB9A 957/4885ALDH1A1 1006/4885
US-20250346597-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES DGKG, DGKA, DGKK NPC1 1908/4885RAB9A 1548/4885ALDH1A1 4075/4885
US-20210315869-A1 COMPOUNDS AND METHODS FOR CSK MODULATION AND INDICATIONS THEREFOR MC2R, SLC10A1, SLC10A2 NPC1 736/4885RAB9A 1236/4885ALDH1A1 2544/4885
US-20090258855-A1 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS MAP3K20, TTK, PRKACB NPC1 2325/4885RAB9A 2145/4885ALDH1A1 4730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.